Novel vectors and approaches for gene therapy in liver diseases

2019 Blaese, 1995, T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years, Science, 270, 475, 10.1126/science.270.5235.475 Bordignon, 1995, Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients, Science, 270, 470, 10.1126/science.270.5235.470 Raper, 2003, Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol Genet Metab, 80, 148, 10.1016/j.ymgme.2003.08.016 Hacein-Bey-Abina, 2003, A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency, N Engl J Med, 348, 255, 10.1056/NEJM200301163480314 Ginn, 2018, Gene therapy clinical trials worldwide to 2017: an update, J Gene Med, 20, 10.1002/jgm.3015 Shahryari, 2019, Development and clinical translation of approved gene therapy products for genetic disorders, Front Genet, 10, 868, 10.3389/fgene.2019.00868 Bulaklak, 2020, The once and future gene therapy, Nat Commun, 11, 5820, 10.1038/s41467-020-19505-2 Cozmescu, 2021, Gene therapies targeting the liver, J Hepatol, 74, 235, 10.1016/j.jhep.2020.08.003 Baruteau, 2017, Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects, J Inherit Metab Dis, 40, 497, 10.1007/s10545-017-0053-3 Zabaleta, 2019, Genetic-based approaches to inherited metabolic liver diseases, Hum Gene Ther, 30, 1190, 10.1089/hum.2019.140 Coutinho, 2016, Genetic substrate reduction therapy: a promising approach for lysosomal storage disorders, Diseases, 4, 33, 10.3390/diseases4040033 Pankowicz, 2017, CRISPR/Cas9: at the cutting edge of hepatology, Gut, 66, 1329, 10.1136/gutjnl-2016-313565 Quiviger, 2018, Improved molecular platform for the gene therapy of rare diseases by liver protein secretion, Eur J Med Genet, 61, 723, 10.1016/j.ejmg.2018.04.010 Arruda, 2020, Gene therapy for hemophilia: facts and quandaries in the 21st century, Mediterr J Hematol Infect Dis, 12 Leal, 2020, Lysosomal storage diseases: current therapies and future alternatives, J Mol Med, 98, 931, 10.1007/s00109-020-01935-6 Song, 2002, Hydrodynamics-based transfection: simple and efficient method for introducing and expressing transgenes in animals by intravenous injection of DNA, Methods Enzymol, 346, 92, 10.1016/S0076-6879(02)46050-8 Zhang, 1999, High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA, Hum Gene Ther, 10, 1735, 10.1089/10430349950017734 Sandra, 2018, Translational advances of hydrofection by hydrodynamic injection, Genes, 9, 136, 10.3390/genes9030136 Yokoo, 2016, Liver-targeted hydrodynamic gene therapy: recent advances in the technique, World J Gastroenterol, 22, 8862, 10.3748/wjg.v22.i40.8862 Heller, 1996, In vivo gene electroinjection and expression in rat liver, FEBS Lett, 389, 225, 10.1016/0014-5793(96)00590-X Sutter, 2020, In vivo electroporation-mediated, intrahepatic Alpha1 antitrypsin gene transfer reduces pulmonary emphysema in pallid mice, Pharmaceutics, 12, 793, 10.3390/pharmaceutics12090793 Endo-Takahashi, 2020, Microbubbles and nanobubbles with ultrasound for systemic gene delivery, Pharmaceutics, 12, 964, 10.3390/pharmaceutics12100964 Noble-Vranish, 2018, Ultrasound-mediated gene therapy in swine livers using single-element, multi-lensed, high-intensity ultrasound transducers, Mol Ther Methods Clin Dev, 10, 179, 10.1016/j.omtm.2018.06.008 Heng, 2004, Chromatin loops are selectively anchored using scaffold/matrix-attachment regions, J Cell Sci, 117, 999, 10.1242/jcs.00976 Giannakopoulos, 2019, Efficient episomal gene transfer to human hepatic cells using the pFAR4-S/MAR vector, Mol Biol Rep, 46, 3203, 10.1007/s11033-019-04777-9 McClintock, 1941, The stability of broken ends of chromosomes in zea mays, Genetics, 26, 234, 10.1093/genetics/26.2.234 Nishihara, 2019, Evolution of transposable elements and evolution of eukaryote genomes mediated by transposable elements, Genes Genet Syst, 94, 231, 10.1266/ggs.94.231 Podetz-Pedersen, 2016, A broad range of dose optima achieve high-level, long-term gene expression after hydrodynamic delivery of sleeping beauty transposons using hyperactive SB100x transposase, Mol Ther Nucleic Acids, 5, e279, 10.1038/mtna.2015.54 Hackett, 2011, Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies, Curr Gene Ther, 11, 341, 10.2174/156652311797415827 Nakanishi, 2010, piggyBack transposon-mediated long-term gene expression in mice, Mol Ther, 18, 707, 10.1038/mt.2009.302 Di Matteo, 2014, Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy, Mol Ther, 22, 1614, 10.1038/mt.2014.131 Ruiz de Galarreta, 2017, Therapeutic editing of hepatocyte genome in vivo, J Hepatol, 67, 818, 10.1016/j.jhep.2017.05.012 Laoharawee, 2018, Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing, Mol Ther, 26, 1127, 10.1016/j.ymthe.2018.03.002 Ou, 2019, ZFN-mediated in vivo genome editing corrects murine hurler syndrome, Mol Ther, 27, 178, 10.1016/j.ymthe.2018.10.018 Alves-Bezerra, 2019, Using CRISPR/Cas9 to model human liver disease, JHEP Rep, 1, 392, 10.1016/j.jhepr.2019.09.002 Uddin, 2020, CRISPR gene therapy: applications, limitations, and implications for the future, Front Oncol, 10, 1387, 10.3389/fonc.2020.01387 Xu, 2020, CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity, Int J Biol Sci, 16, 2283, 10.7150/ijbs.33481 Gong, 2020, A versatile nonviral delivery system for multiplex gene-editing in the liver, Adv Mater, 32, 10.1002/adma.202003537 Zabaleta, 2018, CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I, Nat Commun, 9, 5454, 10.1038/s41467-018-07827-1 Pankowicz, 2016, Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia, Nat Commun, 7, 12642, 10.1038/ncomms12642 Huang, 2017, Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics, Mol Ther Nucleic Acids, 6, 116, 10.1016/j.omtn.2016.12.003 Debacker, 2020, Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug, Mol Ther, 28, 1759, 10.1016/j.ymthe.2020.06.015 Balwani, 2020, Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria, N Engl J Med, 382, 2289, 10.1056/NEJMoa1913147 Liebow, 2017, An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria, J Am Soc Nephrol, 28, 494, 10.1681/ASN.2016030338 Levin, 2019, Treating disease at the RNA level with oligonucleotides, N Engl J Med, 380, 57, 10.1056/NEJMra1705346 Alkhouri, 2020, Oligonucleotide-based therapeutics: an emerging strategy for the treatment of chronic liver diseases, Hepatology Mahpour, 2020, Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy, JHEP Rep, 3, 100177, 10.1016/j.jhepr.2020.100177 Lungwitz, 2005, Polyethylenimine-based non-viral gene delivery systems, Eur J Pharm Biopharm, 60, 247, 10.1016/j.ejpb.2004.11.011 Xue, 2021, PEI fluorination reduces toxicity and promotes liver-targeted siRNA delivery, Drug Deliv Transl Res, 11, 255, 10.1007/s13346-020-00790-9 Witzigmann, 2020, Lipid nanoparticle technology for therapeutic gene regulation in the liver, Adv Drug Deliv Rev, 159, 344, 10.1016/j.addr.2020.06.026 Semple, 2010, Rational design of cationic lipids for siRNA delivery, Nat Biotechnol, 28, 172, 10.1038/nbt.1602 Wei, 2020, Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4-/- mouse model of PFIC3, J Hepatol, 20 Jiang, 2020, Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia, Nat Commun, 11, 5339, 10.1038/s41467-020-19156-3 Truong, 2019, Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency, Proc Natl Acad Sci U S A, 116, 21150, 10.1073/pnas.1906182116 Cao, 2019, mRNA therapy improves metabolic and behavioral abnormalities in a murine model of citrin deficiency, Mol Ther, 27, 1242, 10.1016/j.ymthe.2019.04.017 An, 2017, Systemic messenger RNA therapy as a treatment for methylmalonic acidemia, Cell Rep, 21, 3548, 10.1016/j.celrep.2017.11.081 Jiang, 2018, Systemic messenger RNA as an etiological treatment for acute intermittent porphyria, Nat Med, 24, 1899, 10.1038/s41591-018-0199-z Prieve, 2018, Targeted mRNA therapy for ornithine transcarbamylase deficiency, Mol Ther, 26, 801, 10.1016/j.ymthe.2017.12.024 Akinc, 2019, The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs, Nat Nanotechnol, 14, 1084, 10.1038/s41565-019-0591-y Luigetti, 2021, Patisiran in hereditary transthyretin-mediated amyloidosis, Lancet Neurol, 20, 21, 10.1016/S1474-4422(20)30397-5 Ray, 2020, Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol, N Engl J Med, 382, 1507, 10.1056/NEJMoa1912387 El Dika, 2019, An open-label, multicenter, phase I, dose escalation study with phase II expansion cohort to determine the safety, pharmacokinetics, and preliminary antitumor activity of intravenous TKM-080301 in subjects with advanced hepatocellular carcinoma, Oncologist, 24, 10.1634/theoncologist.2018-0838 Alexopoulou, 2020, New approaches to the treatment of chronic hepatitis B, J Clin Med, 9, 3187 Conway, 2019, Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets, Mol Ther, 27, 866, 10.1016/j.ymthe.2019.03.003 Daya, 2008, Gene therapy using adeno-associated virus vectors, Clin Microbiol Rev, 21, 583, 10.1128/CMR.00008-08 Hastie, 2015, Recombinant adeno-associated virus vectors in the treatment of rare diseases, Expert Opin Orphan Drugs Inform Healthc, 675, 10.1517/21678707.2015.1039511 Palaschak, 2019, AAV-mediated gene delivery to the liver: overview of current technologies and methods, Methods Mol Biol, 1950, 333, 10.1007/978-1-4939-9139-6_20 Peyvandi, 2019, Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia, Haemophilia, 25, 738, 10.1111/hae.13816 Vercauteren, 2016, Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid, Mol Ther, 24, 1042, 10.1038/mt.2016.61 Büning, 2019, Capsid modifications for targeting and improving the efficacy of AAV vectors, Mol Ther Methods Clin Dev, 12, 248, 10.1016/j.omtm.2019.01.008 Mével, 2020, Chemical modification of the adeno-associated virus capsid to improve gene delivery, Chem Sci, 11, 1122, 10.1039/C9SC04189C Westhaus, 2020, High-throughput in vitro, ex vivo, and in vivo screen of adeno-associated virus vectors based on physical and functional transduction, Hum Gene Ther, 31, 575, 10.1089/hum.2019.264 Koerber, 2008, DNA shuffling of adeno-associated virus yields functionally diverse viral progeny, Mol Ther, 16, 1703, 10.1038/mt.2008.167 Lisowski, 2014, Selection and evaluation of clinically relevant AAV variants in a xenograft liver model, Nature, 506, 382, 10.1038/nature12875 Paulk, 2018, Bioengineered AAV capsids with combined high human liver transduction in vivo and unique humoral seroreactivity, Mol Ther, 26, 289, 10.1016/j.ymthe.2017.09.021 Li, 2015, Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors, Mol Ther, 23, 1867, 10.1038/mt.2015.174 Ling, 2016, Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors, Mol Ther Methods Clin Dev, 3, 16029, 10.1038/mtm.2016.29 Biswas, 2020, Engineering and in vitro selection of a novel AAV3B variant with high hepatocyte tropism and reduced seroreactivity, Mol Ther Methods Clin Dev, 19, 347, 10.1016/j.omtm.2020.09.019 Rangarajan, 2017, AAV5-Factor VIII gene transfer in severe hemophilia A, N Engl J Med, 377, 2519, 10.1056/NEJMoa1708483 Manno, 2006, Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nat Med, 12, 342, 10.1038/nm1358 Nathwani, 2011, Adenovirus-associated virus vector-mediated gene transfer in hemophilia B, N Engl J Med, 365, 2357, 10.1056/NEJMoa1108046 High, 2018, A phase 1/2 trial of investigational Spk-8011 in hemophilia a demonstrates durable expression and prevention of bleeds, Blood, 132, 487, 10.1182/blood-2018-99-115495 George, 2017, Hemophilia B gene therapy with a high specific- activity factor IX variant, N Engl J Med, 377, 2215, 10.1056/NEJMoa1708538 Pasi, 2020, Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A, N Engl J Med, 382, 29, 10.1056/NEJMoa1908490 D'Avola, 2016, Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria, J Hepatol, 65, 776, 10.1016/j.jhep.2016.05.012 Nakai, 2001, Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo, J Virol, 75, 6969, 10.1128/JVI.75.15.6969-6976.2001 Borel, 2017, Survival advantage of both human hepatocyte xenografts and genome-edited hepatocytes for treatment of α-1 antitrypsin deficiency, Mol Ther, 25, 2477, 10.1016/j.ymthe.2017.09.020 Barzel, 2015, Promoterless gene targeting without nucleases ameliorates haemophilia B in mice, Nature, 517, 360, 10.1038/nature13864 Porro, 2017, Promoterless gene targeting without nucleases rescues lethality of a Crigler-Najjar syndrome mouse model, EMBO Mol Med, 9, 1346, 10.15252/emmm.201707601 Chandler, 2020, Promoterless, nuclease-free genome editing confers a growth advantage for corrected hepatocytes in mice with methylmalonic acidemia, Hepatology De Caneva, 2019, Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases, JCI Insight, 5 Chatterjee, 2020, Adeno-associated virus and hematopoietic stem cells: the potential of adeno-associated virus hematopoietic stem cells in genetic medicines, Hum Gene Ther, 31, 542, 10.1089/hum.2020.049 Conboy, 2018, Making gene editing a therapeutic reality, F1000Res, 7, 10.12688/f1000research.16106.1 Ginn, 2019, Efficient in vivo editing of OTC-deficient patient-derived primary human hepatocytes, JHEP Rep, 2, 100065, 10.1016/j.jhepr.2019.100065 Ran, 2015, In vivo genome editing using Staphylococcus aureus Cas9, Nature, 520, 186, 10.1038/nature14299 Siew, 2019, Prevention of cholestatic liver disease and reduced tumorigenicity in a murine model of PFIC type 3 using hybrid AAV-piggyBac gene therapy, Hepatology, 70, 2047, 10.1002/hep.30773 Cunningham, 2015, Modeling correction of severe urea cycle defects in the growing murine liver using a hybrid recombinant adeno-associated virus/piggyback transposase gene delivery system, Hepatology, 62, 417, 10.1002/hep.27842 La, 2020, Use of a hybrid adeno-associated viral vector transposon system to deliver the insulin gene to diabetic NOD mice, Cells, 9, 2227, 10.3390/cells9102227 Gao, 2019, State-of-the-art human adenovirus vectorology for therapeutic approaches, FEBS Lett, 593, 3609, 10.1002/1873-3468.13691 Ricobaraza, 2020, High-capacity adenoviral vectors: expanding the scope of gene therapy, Int J Mol Sci, 21, 3643, 10.3390/ijms21103643 Castello, 2016, Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1, Gene Ther, 23, 129, 10.1038/gt.2015.107 Leggiero, 2019, Helper-dependent adenovirus-mediated gene transfer of a secreted LDL receptor/transferrin chimeric protein reduces aortic atherosclerosis in LDL receptor-deficient mice, Gene Ther, 26, 121, 10.1038/s41434-019-0061-z Somanathan, 2020, Adenovirus-antibody complexes contributed to lethal systemic inflammation in a gene therapy trial, Mol Ther, 28, 784, 10.1016/j.ymthe.2020.01.006 Shirley, 2020, Immune responses to viral gene therapy vectors, Mol Ther, 28, 709, 10.1016/j.ymthe.2020.01.001 Liu, 2020, Helper virus-free gutless adenovirus (HF-GLAd): a new platform for gene therapy, BMB Rep, 53, 565, 10.5483/BMBRep.2020.53.11.185 Sun, 2019, Exploring the functions of polymers in adenovirus-mediated gene delivery: evading immune response and redirecting tropism, Acta Biomate, 97, 93, 10.1016/j.actbio.2019.06.059 Palmer, 2020, A single "All-in-One" helper-dependent adenovirus to deliver donor DNA and CRISPR/Cas9 for efficient homology-directed repair, Mol Ther Methods Clin Dev, 17, 441, 10.1016/j.omtm.2020.01.014 Palmer, 2019, Bi-allelic homology-directed repair with helper dependent adenoviruses, Mol Ther Methods Clin Dev, 15, 285, 10.1016/j.omtm.2019.10.003 Hausl, 2010, Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B, Mol Ther, 18, 1896, 10.1038/mt.2010.169 Ferry, 2011, Retroviral vector-mediated gene therapy for metabolic diseases: an update, Curr Pharm Des, 17, 2516, 10.2174/138161211797247587 Poletti, 2019, Gene-based approaches to inherited neurometabolic diseases, Hum Gene Ther, 30, 1222, 10.1089/hum.2019.190 Kay, 1992, Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes, Proc Natl Acad Sci U S A, 89, 89, 10.1073/pnas.89.1.89 Grossman, 1992, Transplantation of genetically modified autologous hepatocytes into nonhuman primates: feasibility and short-term toxicity, Hum Gene Ther, 3, 501, 10.1089/hum.1992.3.5-501 Overturf, 1996, Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I, Nat Genet, 12, 266, 10.1038/ng0396-266 Raper, 1996, Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia, Ann Surg, 223, 116, 10.1097/00000658-199602000-00002 Tada, 1998, Long-term amelioration of bilirubin glucuronidation defect in Gunn rats by transplanting genetically modified immortalized autologous hepatocytes, Cell Transpl, 7, 607, 10.1177/096368979800700611 Andreoletti, 2001, Engraftment of autologous retrovirally transduced hepatocytes after intraportal transplantation into nonhuman primates: implication for ex gene therapy, Hum Gene Ther, 12, 169, 10.1089/104303401750061230 Grossman, 1995, A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia, Nat Med, 1, 1148, 10.1038/nm1195-1148 Oertel, 2003, Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes transduced ex vivo with lentiviral vectors, Hepatology, 37, 994, 10.1053/jhep.2003.50183 Bierwolf, 2016, Primary human hepatocytes repopulate livers of mice after in vitro culturing and lentiviral-mediated gene transfer, Tissue Eng Part A, 22, 742, 10.1089/ten.tea.2015.0427 Hickey, 2019, Autologous gene and cell therapy provides safe and long-term curative therapy in A large pig model of hereditary tyrosinemia type 1, Cell Transpl, 28, 79, 10.1177/0963689718814188 Kay, 1993, In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs, Science, 262, 117, 10.1126/science.8211118 Ferry, 1991, Retroviral-mediated gene transfer into hepatocytes in vivo, Proc Natl Acad Sci U S A, 88, 8377, 10.1073/pnas.88.19.8377 Borgnon, 2005, Follistatin allows efficient retroviral-mediated gene transfer into rat liver, Biochem Biophys Res Commun, 328, 937, 10.1016/j.bbrc.2005.01.049 Minami, 2000, Enhancement of retrovirus-mediated gene transfer to rat liver in vivo by infusion of hepatocyte growth factor and triiodothyronine, J Hepatol, 33, 183, 10.1016/S0168-8278(00)80358-X Oh, 1999, An efficient retrovirus-mediated transduction of human blood coagulation factor VIII cDNA in regenerating rat liver, Ann Hematol, 78, 213, 10.1007/s002770050504 Forbes, 2000, Synergistic growth factors enhance rat liver proliferation and enable retroviral gene transfer via a peripheral vein, Gastroenterology, 118, 591, 10.1016/S0016-5085(00)70266-6 Puppi, 2004, Long term transgene expression by hepatocytes transduced with retroviral vectors requires induction of immune tolerance to the transgene, J Hepatol, 41, 222, 10.1016/j.jhep.2004.04.015 Aubert, 2002, Cytotoxic immune response blunts long-term transgene expression after efficient retroviral-mediated hepatic gene transfer in rat, Mol Ther, 5, 388, 10.1006/mthe.2002.0561 Tada, 1998, Long-term reduction of serum bilirubin levels in Gunn rats by retroviral gene transfer in vivo, Liver Transpl Surg, 4, 78, 10.1002/lt.500040111 Chandler, 2019, Gene therapy for methylmalonic acidemia: past, present, and future, Hum Gene Ther, 30, 1236, 10.1089/hum.2019.113 Clar, 2015, Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice, Hum Mol Genet, 24, 2287, 10.1093/hmg/ddu746 Cantore, 2015, Liver-directed lentiviral gene therapy in a dog model of hemophilia B, Sci Transl Med, 7, 277ra28, 10.1126/scitranslmed.aaa1405 Milani, 2019, Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates, Sci Transl Med, 22 Powell, 2003, Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion, Blood, 102, 2038, 10.1182/blood-2003-01-0167 Muhuri, 2021, Overcoming innate immune barriers that impede AAV gene therapy vectors, J Clin Invest, 131, 10.1172/JCI143780 Kerpel-Fronius, 2020, Development and use of gene therapy orphan drugs-ethical needs for a broader cooperation between the pharmaceutical industry and society, Front Med, 7, 608249, 10.3389/fmed.2020.608249 Chand, 2020, Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy, J Hepatol Verdera, 2020, AAV vector immunogenicity in humans: a long journey to successful gene transfer, Mol Ther, 28, 723, 10.1016/j.ymthe.2019.12.010 Konkle, 2020, BAX 335 hemophilia B gene therapy clinical trial results - potential impact of CpG sequences on gene expression, Blood, 2019004625 Buscara, 2020, Of rAAV and men: from genetic neuromuscular disorder efficacy and toxicity preclinical studies to clinical trials and back, J Pers Med, 10, 258 Salas, 2019, Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates, Blood Adv, 3, 2632, 10.1182/bloodadvances.2019000380 Leborgne, 2020, IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies, Nat Med, 26, 1096, 10.1038/s41591-020-0911-7 La Bella, 2020, Adeno-associated virus in the liver: natural history and consequences in tumour development, Gut, 69, 737, 10.1136/gutjnl-2019-318281 Gil-Farina, 2016, Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients, Mol Ther, 24, 1100, 10.1038/mt.2016.52 George, 2020, Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B, Mol Ther, 28, 2073, 10.1016/j.ymthe.2020.06.001